Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Unexplained Repeated Miscarriages
NCT03970954Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2021
- Primary completion
- Jul 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in recurrent miscarriage (RPL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Variation of rate of blood circulating T regulator lymphocytes (% of CD4 and total) at Day 150. Started Jan 2021; status: completed.
02
Drugs
aldesleukin
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on NCT03970954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970954.